Health ❯ Cardiovascular Health ❯ Risk Factors ❯ Clinical Outcomes
Lilly’s pill underperformance prompted investor sell-off, triggering price cuts plus lawsuits by Novo Nordisk to protect its GLP-1 market lead.
